How to Trade Science and Health Markets on Polymarket
A guide to FDA decisions, clinical trials, space missions and public-health markets: primary sources, timelines, binary risk and the resolution details that decide technical outcomes.

Science and health markets are attractive because the underlying events are technical and the sources are public. They are also difficult because the timelines slip, the language is specialized and the outcome can depend on a regulatory detail rather than the headline result.
The edge is in reading the primary document and understanding the process, not in having a strong opinion about science.
The main science and health market types
- FDA decisions. Approval, rejection, label expansion, advisory committee votes.
- Clinical trials. Endpoints, readouts, phase transitions.
- Public health. Outbreaks, case counts, policy decisions.
- Space. Launch dates, mission success, landings, contracts.
- Energy and climate science. Temperature records, emissions, policy targets.
- Research milestones. Publications, replications, funding.
Each has a different source and a different failure mode. The markets and events documentation explains how Polymarket groups them.
Read the exact endpoint
In health markets, the question often depends on:
- the trial phase;
- the primary endpoint;
- the statistical threshold;
- the patient population;
- the follow-up period;
- the regulator's decision, not the company's press release.
The U.S. Food and Drug Administration is the primary source for approval decisions. A company announcement can be accurate and still not be the resolution event.
The resolution documentation explains the process. If the rule says "FDA approval", a promising trial result is not enough.
Space and launch markets
Space markets depend on:
- the launch window;
- weather;
- technical readiness;
- range availability;
- mission objectives;
- the difference between launch and mission success.
NASA and the operator's official updates are primary sources. A launch can happen and the mission can still fail; a launch can be delayed and the market can resolve NO on a date condition.
Check the exact question: "Will the rocket launch by date X?" is not "Will the mission succeed?"
Timelines slip
Science and health timelines are notoriously uncertain. A trial readout, an FDA decision or a launch can move by weeks or months.
For a date-based market:
- check the official calendar;
- check the historical delay rate;
- check the market's rule for delays;
- avoid assuming that a scheduled date is a likely date.
A market at 80 cents for an event scheduled next week can be expensive if the event is usually delayed. Check the historical delay rate for the specific regulator, trial or launch provider. A schedule is a plan, not a promise. If the market resolves on a date and the event has a history of slipping, the probability of an on-time outcome may be much lower than the calendar suggests.
How to read a clinical trial readout
A trial readout is not a single number. Check the phase, the primary endpoint, the statistical significance, the confidence interval, the patient population and the follow-up period. A result can be statistically significant and clinically modest. A secondary endpoint can look strong while the primary endpoint misses. A company press release may emphasize the positive subgroup and bury the overall result. Read the actual release and, where available, the registry entry or publication. If the market question is about regulatory approval, the trial result is one input, not the decision. The same discipline applies to space missions: a launch is not a mission success, and a mission success is not a contract.
Binary risk and position sizing
Science and health markets are binary and often low-liquidity. A positive trial readout can be followed by a regulatory rejection; a launch can succeed and a contract can be cancelled. Use small risk per market, a cap per company or mission, a cash buffer, a rule for delayed resolution and a plan for a surprise regulatory decision. If the market is thin, assume the exit will be worse than the entry and size accordingly. The liquidity guide explains how to estimate the exit cost.
The risk management guide covers the math.
A science/health checklist
- Exact event and endpoint confirmed.
- Resolution source identified.
- Primary document located.
- Timeline and delay history checked.
- Difference between announcement and decision confirmed.
- Liquidity and spread checked.
- Correlated exposure checked.
- Position size within risk budget.
- Plan for delay or ambiguity set.
Common mistakes
- Trading a press release as an FDA approval.
- Confusing a trial result with a regulatory decision.
- Ignoring the primary endpoint.
- Assuming a launch date is a launch.
- Sizing a thin market like a liquid one.
- Forgetting that timelines slip.
- Stacking multiple markets on the same company or mission.
Bottom line
Science and health markets reward document reading and process knowledge. Read the exact endpoint, use the primary source, respect timelines and size for binary risk. The science can be fascinating; the trade still depends on the resolution rule.
This article is research and education, not medical, financial or legal advice.
Sources
- 1.Markets and Events— Polymarket Documentation
- 2.Resolution— Polymarket Documentation
- 3.U.S. Food and Drug Administration— U.S. Food and Drug Administration
- 4.NASA— National Aeronautics and Space Administration